Sunday, May 19, 2013 Last update: Yesterday, 8:04 PM
Company Tech News as it Breaks
Questcor Reports Fourth Quarter and Full Year 2012 Results
Submitted by admin on 2/26/2013 @ 1:06 PM
Companies mentioned in this article:
Questcor Pharmaceuticals, Inc.
ANAHEIM, Calif., Feb. 26, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the fourth quarter and full year ended December 31, 2012.
Three Months Ended Three Months Ended
12/31/12 12/31/11 Percentage Change
-------- -------- -----------------
Net
Sales $160.5 Million $75.5 Million 113%
------ -------------- ------------- ---
GAAP
Diluted
EPS $1.03 $0.48 115%
-------- ----- ----- ---
Non-
GAAP
Diluted
EPS $1.09 $0.47 132%
-------- ----- ----- ---
Year Ended 12/31/12 Year Ended 12/31/11 Percentage Change
------------------- ------------------- -----------------
Net
Sales $509.3 Million $218.2 Million 133%
------ -------------- -------------- ---
GAAP
Diluted
EPS $3.14 $1.21 160%
-------- ----- ----- ---
Non-
GAAP
Diluted
EPS $3.33 $1.27 162%
-------- ----- ----- ---
Net sales for the fourth quarter of 2012 were $160.5 million, compared to $75.5 million for the same period in 2011. Net sales increased primarily due to expanded prescribing of H.P. Acthar(®) Gel (repository corticotropin injection) by nephrologists in the treatment of nephrotic syndrome, as well as continued prescribing by neurologists in the treatment of MS relapses and infantile spasms. Net sales also benefitted from the initiation of commercial activities focused on the use of Acthar by rheumatologists in the treatment of on-label rheumatology-related conditions.
GAAP earnings for the fourth quarter of 2012 were $1.03 per diluted common share, compared to $0.48 per diluted common share for last year's comparable quarter. Non-GAAP earnings for the quarter ended December 31, 2012 were $1.09 per diluted common share and exclude non-cash share-based compensation expense and depreciation and amortization expense. Non-GAAP earnings for the year ago quarter were $0.47 per diluted common share. Basic common share count decreased over 5 million shares from the fourth quarter of 2011 to the fourth quarter of 2012.
Questcor shipped 6,330 vials of Acthar during the fourth quarter 2012, up 88 percent compared to 3,360 vials in the year ago quarter. For the full year of 2012, Questcor shipped 20,741vials of Acthar, up 94 percent compared to 10,710 vials in 2011. Quarterly vial shipments are subject to significant variation due to the size and timing of individual orders received from Questcor's distributor. The timing of when these orders are received and filled can significantly affect net sales and net income in any particular quarter.
The fourth quarter and full year results do not reflect Questcor's acquisition of BioVectra or the change, to be applied on a prospective basis, in the Medicaid rebate percentage for Acthar, both of which occurred in the first quarter of 2013.
"Net sales, net income and cash flow from operations grew sharply in the fourth quarter compared to the prior-year period," said Don M. Bailey, President and CEO of Questcor. "Additionally, we more than doubled our investment in R&D in 2012 compared to 2011 as we continue to build the body of evidence regarding the unique properties of Acthar and how it may benefit an increasing number of patients who do not respond to other therapies."
"Acthar is most commonly prescribed by physicians as an appropriate treatment alternative for patients with certain auto-immune conditions in whom first-line therapies have not provided the intended treatment outcome and an additional FDA-approved treatment alternative is needed," commented Steve Cartt, Chief Operating Officer of Questcor. "For such patients, insurance coverage for Acthar continues to remain favorable. Continued expanded use in nephrotic syndrome, MS and strong growth in our newly commercialized rheumatology indications, mainly dermatomyositis and polymyositis, contributed to the year-over-year net sales increase in the fourth quarter. While Acthar net sales in MS posted greater than 40% year-over-year growth, MS prescriptions softened by approximately 8% from the third quarter, after almost five years of sequential quarterly growth, and nephrotic syndrome became the largest contributor to net sales. At the same time, based on early, encouraging results from our pilot rheumatology commercial effort, we have just completed our rheumatology sales force expansion from 12 to 55 representatives."
"We continue to invest in the future of both Acthar and our overall business capabilities," continued Mr. Bailey. "In addition to the rapid expansion of our R&D investment, we have also substantially expanded our sales force, our reimbursement and compliance teams, and our manufacturing capabilities. The recent acquisition of BioVectra, which gives us much greater control of our supply chain, deepens our manufacturing capabilities and scientific expertise, while also expanding and diversifying our business. The appointment of Michael Aldridge to lead our strategic development function was another important step as we look to broaden our capabilities and further diversify our business, while maintaining our focus on the potential of Acthar to help many more patients than it does today. We continue to balance our investments in the business with a disciplined program of returning capital to shareholders, as demonstrated by additional share repurchases and the institution of a regular quarterly dividend."
Full Year Financial Results
Net sales for the full year of 2012 were $509.3 million, compared to $218.2 million in the full year of 2011. Cash flow from operations for the full year of 2012 was $219.0 million, compared to $85.6 million for the full year of 2011. GAAP earnings per share for the full year of 2012 were $3.14 per diluted common share, compared with $1.21 per diluted common share for the comparable period of 2011. Non-GAAP earnings per share for the full year ended December 31, 2012 were $3.33 per diluted common share, excluding non-cash share-based compensation expense, depreciation and amortization expense, and impairment of intangibles. Non-GAAP earnings for the comparable period of 2011 were $1.27 per diluted common share.
Research and Development Programs
Questcor's continued strong financial performance has enabled the company to increase investment in research programs to further clarify the potential immune-modulating properties of Acthar and identify Acthar mechanisms of action applicable to other inflammatory and auto-immune diseases with high unmet need. Questcor currently has approximately 35 company-sponsored clinical and pre-clinical research projects underway. Key company-sponsored clinical programs are in process in the following disease states:
-- Lupus: Enrollment is underway in a company-sponsored multi-site Phase 4
clinical trial to evaluate the efficacy and safety of daily Acthar
administration over a 6-month period in patients with persistently
active lupus.
-- Idiopathic Membranous Nephropathy: Enrollment continues in a
company-sponsored Phase 4 trial in idiopathic membranous nephropathy.
Patients enrolled in this study are refractory, or non-responsive, to
current standard therapies or have relapsed after partial remission on
current standard therapies.
-- Diabetic Nephropathy: Enrollment continues in a company-sponsored Phase
2 trial to evaluate the efficacy and safety of Acthar in patients with
diabetic nephropathy, one of the most common causes of end-stage renal
disease in the United States.
-- Amyotrophic Lateral Sclerosis (ALS): Questcor is in discussions with the
U.S. Food and Drug Administration (FDA) to commence clinical trials of
Acthar for the treatment of amyotrophic lateral sclerosis (ALS), often
referred to as Lou Gehrig's disease. ALS is a life-threatening,
progressive neurodegenerative disease that affects nerve cells in the
brain and the spinal cord. The company expects to file an
Investigational New Drug application (IND) and initiate a
proof-of-concept trial of Acthar in ALS in the first half of 2013.
In addition, Questcor provides grant funding to a wide range of independent research projects, which include the evaluation of Acthar in nephrotic syndrome due to focal segmental glomerulosclerosis (FSGS), nephrotic syndrome due to lupus nephritis, lupus flares, intractable chronic migraine, multiple sclerosis, prevention of infantile spasms in at-risk patients, and others. The company is currently funding more than 30 such independent research programs, including both preclinical and clinical studies.
Questcor continues to receive case reports and inquiries from physicians indicating that Acthar may be able to benefit patients whose serious illnesses are not effectively treated with other medications, but for which Questcor does not currently have an active sales force providing information to specialists who treat these illnesses. As it has over the last several years, Questcor continues to follow up on these reports and inquiries in order to ascertain whether the Company should fund research regarding the potential utility of Acthar in treating these serious illnesses. Past reports and inquiries have led to the company's current work in MS and rheumatology. More recent reports and inquiries may lead Questcor to expand its internal research and development, including clinical trials, and other activities within current on-label or potential new indications.
Share Repurchase Program and Cash Dividend
During the fourth quarter of 2012, Questcor used $18.6 million in cash to repurchase 747,207 shares of its common stock in open market transactions, at an average price of $24.93 per common share. Since the beginning of 2008, the company has repurchased a total of 22.2 million shares of its common stock for $340.3 million through December 31, 2012, at an average price of $15.36 per share. As of December 31, 2012, there are approximately 6.3 million shares authorized remaining under the stock repurchase plan. Shares outstanding were 58.5 million at December 31, 2012 and 63.6 million at December 31, 2011.
The company today announced that its Board of Directors has declared a quarterly cash dividend of $0.25 per share to all shareholders of record at the close of business on April 22, 2013. The quarterly cash dividend was increased from $0.20 per share, or 25% over the previous quarterly dividend. The dividend is scheduled to be paid on or about April 30, 2013. Questcor currently intends to pay regular quarterly cash dividends for the foreseeable future.
2012 Corporate Highlights
-- During 2012, approximately 7,000 patients received new prescriptions for
Acthar.
-- During 2012, additional academic papers were published providing
incremental information regarding Acthar and its potential
immuno-modulating properties and mechanisms of action.
-- During 2012, Questcor initiated two multi-center clinical trials,
continued enrollment in a third, and initiated discussions with the FDA
for a fourth trial.
-- During the second quarter of 2012, the company completed the expansion
of its Nephrology sales force to 58 from 28 representatives.
-- In the third quarter of 2012, the company completed the expansion of its
neurology sales force to 107 from 77 representatives.
-- In the third quarter of 2012, Questcor initiated commercial efforts for
Acthar in the treatment of rheumatology-related indications already
included on the FDA-approved package insert for Acthar. Acthar is
indicated for multiple FDA-approved rheumatology-related conditions,
including its use as adjunctive therapy in psoriatic arthritis,
rheumatoid arthritis, juvenile rheumatoid arthritis, and ankylosing
spondylitis. Acthar is also approved by the FDA as acute or maintenance
therapy in selected cases of systemic lupus erythematosus and systemic
dermatomyositis (polymyositis).
-- In the fourth quarter of 2012, the company initiated the expansion of
its rheumatology sales force to 55 from 12 rheumatology representatives.
-- Questcor also continued to demonstrate its commitment to returning
capital to shareholders, by expanding its common share repurchase
program authorization by an additional 5 million shares and adopting a
policy to pay a regular quarterly dividend in September 2012. The
company repurchased 6.8 million shares in 2012.
Following the end of the fourth quarter of 2012:
-- On January 18, 2013, Questcor acquired BioVectra Inc. for an upfront
payment of $50.8 million. BioVectra has been Questcor's manufacturing
partner for the active pharmaceutical ingredient (API) in Acthar for
nearly a decade. The acquisition further secures the manufacturing
process trade secrets surrounding Acthar.
-- During the first quarter of 2013, the Medicaid rebate amount for Acthar
was reset to the standard basic rebate.
-- On January 28, 2013, Questcor strengthened its management team with the
appointment of Michael Aldridge to the new position of Senior Vice
President, Corporate Strategic Development. Mr. Aldridge's primary
responsibilities will be the identification and development of
partnership and acquisition opportunities to leverage Questcor's
business model. Over time, such initiatives may include development
programs or products complementary to Acthar and the evaluation of
potential expansion into ex-US markets.
Acthar Label Information
The product label for Acthar includes 19 FDA-approved indications. Substantially all of the Company's net sales currently result from Acthar prescriptions for the following on-label indications of:
-- Nephrotic Syndrome (NS): "to induce a diuresis or a remission of
proteinuria in the nephrotic syndrome without uremia of the idiopathic
type or that due to lupus erythematosus." NS can result from several
underlying conditions, and prescribing physicians indicate that Acthar
is most commonly being prescribed for patients who suffer from NS due to
idiopathic membranous nephropathy, focal segmental glomerulosclerosis
(FSGS), IgA nephropathy, minimal change disease and lupus nephritis.
-- Multiple Sclerosis (MS): "for the treatment of acute exacerbations of
multiple sclerosis in adults. Clinical controlled trials have shown H.P.
Acthar Gel to be effective in speeding the resolution of acute
exacerbations of multiple sclerosis. However, there is no evidence that
it affects the ultimate outcome or natural history of the disease." When
Acthar is used, it is typically prescribed as second line treatment for
patients with MS exacerbations.
-- Infantile Spasms (IS): "as monotherapy for the treatment of infantile
spasms in infants and children under 2 years of age."
-- Collagen Diseases: "during an exacerbation or as maintenance therapy in
selected cases of: systemic lupus erythematosus, systemic
dermatomyositis (polymyositis)."
-- Rheumatic Disorders: "as adjunctive therapy for short-term
administration (to tide the patient over an acute episode or
exacerbation) in: Psoriatic arthritis, Rheumatoid arthritis, including
juvenile rheumatoid arthritis (selected cases may require low-dose
maintenance therapy), Ankylosing spondylitis."
Non-GAAP Financial Measures
The company believes it is important to share non-GAAP financial metrics with shareholders as these metrics may better represent the ongoing economics of the business and reflect how we manage the business. Accordingly, management believes investors' understanding of the company's financial performance is enhanced as a result of the disclosure of these non-GAAP financial metrics. Non-GAAP net income should not be viewed in isolation, or as a substitute for, or as superior to, reported GAAP net income. The reconciliation between GAAP and Non-GAAP net income is provided with the financial tables included with this release.
Conference Call and Webcast and Investor Communications
The company will host a conference call and slide presentation via webcast today, February 26, 2013, at 4:30 p.m. ET/ 1:30 p.m. PT. The call can be accessed three ways:
-- By webcast: At Questcor's investor relations website,
http://ir.questcor.com/.
-- By telephone: For both "listen-only" participants and those participants
who wish to take part in the question-and-answer portion of the call,
the telephone dial-in number in the U.S. is (877) 354-0215. For
participants outside the U.S., the dial-in number is (253) 237-1173.
-- By audio replay: A replay of the conference call will be available for
seven business days following conclusion of the live call. The dial-in
number for U.S. participants is (855) 859-2056. For participants outside
the U.S., the replay dial-in number is (404) 537-3406. The replay access
code for all callers is 95427085.
About Questcor
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Questcor's primary product is H.P. Acthar(®) Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from the following on-label indications: the treatment of proteinuria in the nephrotic syndrome of the idiopathic type, or NS, the treatment of acute exacerbations of multiple sclerosis, or MS, in adults, the treatment of infantile spasms, or IS, in infants and children under two years of age, and the treatment of certain rheumatology related conditions, including the treatment of the rare and closely related neuromuscular disorders dermatomyositis and polymyositis. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus. Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. For more information about Questcor, please visit www.questcor.com.
Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "believes," "continue," "could," "estimates," "expects," "growth," "may," "plans," "potential," "remain," "should," "substantial" or "will" or the negative of such terms and other comparable terminology. These statements are only predictions. Actual events or results may differ materially. Factors that could cause or contribute to such differences include, but are not limited to, the following:
-- Our reliance on Acthar for substantially all of our net sales and
profits;
-- Reductions in vials used per prescription resulting from changes in
treatment regimens by physicians or patient compliance with physician
recommendations;
-- Our ability to receive high reimbursement levels from third party
payers;
-- The complex nature of our manufacturing process and the potential for
supply disruptions or other business disruptions;
-- The lack of patent protection for Acthar; and the possible FDA approval
and market introduction of competitive products;
-- Our ability to continue to generate revenue from sales of Acthar to
treat on-label indications associated with NS, MS, IS or
rheumatology-related conditions, and our ability to develop other
therapeutic uses for Acthar;
-- Research and development risks, including risks associated with
Questcor's work in the area of NS and Lupus, our reliance on
third-parties to conduct research and development, and the ability of
research and development to generate successful results;
-- The results of any pending or future litigation, investigations or
claims, including with respect to the investigation by the United States
Attorney's Office for the Eastern District of Pennsylvania regarding the
company's promotional practices and litigation brought by certain
shareholders arising from the federal securities laws, currently pending
in the United States District Court for the Central District of
California;
-- Our ability to comply with federal and state regulations, including
regulations relating to pharmaceutical sales and marketing practices;
-- Regulatory changes or other policy actions by governmental authorities
and other third parties in connection with U.S. health care reform or
efforts to reduce federal and state government deficits;
-- An increase in the proportion of our Acthar unit sales comprised of
Medicaid-eligible patients and government entities;
-- Our ability to estimate reserves required for Acthar used by government
entities and Medicaid-eligible patients and the impact that unforeseen
invoicing of historical Medicaid prescriptions may have upon our
results;
-- Our ability to effectively manage our growth, including the expansion of
our sales forces, and our reliance on key personnel;
-- Our ability to integrate the BioVectra business with our business and to
manage, and grow, a contract manufacturing business;
-- Our ability to comply with foreign regulations related to the operation
of BioVectra's business;
-- The impact to our business caused by economic conditions;
-- Our ability to protect our proprietary rights;
-- The risk of product liability lawsuits;
-- Unforeseen business interruptions and security breaches;
-- Volatility in Questcor's monthly and quarterly Acthar shipments,
estimated channel inventory, and end-user demand, as well as volatility
in our stock price;
-- Our ability and willingness to continue to pay our quarterly dividend or
make future increases in our quarterly dividend; and
-- Other risks discussed in Questcor's annual report on Form 10-K for the
year ended December 31, 2011 as filed with the Securities and Exchange
Commission, or SEC, on February 22, 2012, and other documents filed with
the SEC.
The risk factors and other information contained in these documents should be considered in evaluating Questcor's prospects and future financial performance.
Questcor undertakes no obligation to publicly release the result of any revisions to these forward-looking statements, which may be made to reflect events or circumstances after the date of this release.
For more information, please visit www.questcor.com or www.acthar.com.
Questcor Pharmaceuticals, Inc.
Consolidated Statements of Income
(In thousands, except per share amounts)
Three Months Ended Twelve Months Ended
December 31, December 31,
------------------- --------------------
2012 2011 2012 2011
---- ---- ---- ----
Net sales $160,532 $75,535 $509,292 $218,169
Cost of sales
(exclusive of
amortization of
purchased technology) 9,156 4,013 28,555 12,459
----- ----- ------ ------
Gross profit 151,376 71,522 480,737 205,710
Operating expenses:
Selling and marketing 33,051 16,998 114,139 56,728
General and
administrative 11,175 5,766 33,596 17,743
Research and
development 12,122 5,730 34,269 16,778
Depreciation and
amortization 268 292 1,219 1,044
Impairment of goodwill
and intangibles - - 987 299
--- --- --- ---
Total operating
expenses 56,616 28,786 184,210 92,592
------ ------ ------- ------
Income from operations 94,760 42,736 296,527 113,118
Other income:
Interest and other
income, net 167 145 703 627
--- --- --- ---
Total other income 167 145 703 627
--- --- --- ---
Income before income
taxes 94,927 42,881 297,230 113,745
Income tax expense 32,987 11,240 99,555 34,154
Net income $61,940 $31,641 $197,675 $79,591
======= ======= ======== =======
Net income per share
applicable to common
shareholders:
Basic $1.07 $0.50 $3.28 $1.27
===== ===== ===== =====
Diluted $1.03 $0.48 $3.14 $1.21
===== ===== ===== =====
Shares used in
computing net income
per share applicable
to common
shareholders:
Basic 58,009 63,236 60,243 62,498
====== ====== ====== ======
Diluted 60,266 66,565 63,045 66,010
====== ====== ====== ======
Dividends declared per
common shareholder $0.20 $ - $0.40 $ -
===== ============ ===== ==============
Reconciliation of Non-
GAAP Adjusted
Financial
----------------------
Adjusted net income $65,705 $31,584 $209,644 $83,956
Share-based
compensation expense
(1) (3,590) (1,416) (10,502) (5,128)
Depreciation and
amortization expense
(2) (175) (216) (811) (731)
Impairment of goodwill
and intangibles (3) 0 - (656) (209)
Tax adjustments (4) 0 1,689 0 1,703
Net income - GAAP $61,940 $31,641 $197,675 $79,591
======= ======= ======== =======
Adjusted net income per
share -basic $1.13 $0.50 $3.48 $1.34
Share-based
compensation expense
(1) (0.06) (0.02) (0.17) (0.08)
Depreciation and
amortization expense
(2) (0.00) (0.00) (0.01) (0.01)
Impairment of goodwill
and intangibles (3) 0.00 0.00 (0.01) 0.00
Tax adjustments (4) 0.00 0.03 0.00 0.03
Net income per share -
basic $1.07 $0.50 $3.28 $1.27
===== ===== ===== =====
Adjusted net income per
share -diluted $1.09 $0.47 $3.33 $1.27
Share-based
compensation expense
(1) (0.06) (0.02) (0.17) (0.08)
Depreciation and
amortization expense
(2) (0.00) (0.00) (0.01) (0.01)
Impairment of goodwill
and intangibles (3) 0.00 0.00 (0.01) 0.00
Tax adjustments (4) 0.00 0.03 0.00 0.03
Net income per share -
diluted $1.03 $0.48 $3.14 $1.21
===== ===== ===== =====
Net income per share - basic and diluted
may not foot due to rounding.
Use of Non-GAAP Financial Measures
Our "non-GAAP adjusted net income"
excludes the following items from GAAP
net income:
1. Share-
based
compensation
expense.
2.
Depreciation
and
amortization
expense
3. Impairment
of purchased
technology in
2012 related
to the
acquisition
of Doral and
impairment of
goodwill
related to
the write-
off of
goodwill
associated
with an
acquisition
completed in
1999, written
off in 2011.
4. Tax
adjustments
include: (1)
the valuation
allowance we
established
in the fourth
quarter of
2010 relating
to our single
sales factor
apportionment
election
which was
made in 2011
for
California;
and (2) the
recording of
a one-time
tax credit in
2011 for the
orphan drug
designation.
Questcor Pharmaceuticals, Inc.
Consolidated Balance Sheets
(In thousands, except per share amounts)
December 31, December 31,
2012 2011
---- ----
ASSETS
Current assets:
Cash and cash equivalents $80,608 $88,469
Short-term investments 74,705 121,680
------ -------
Total cash, cash equivalents and
short-term investments 155,313 210,149
Accounts receivable, net of
allowance for doubtful accounts
of $0 at both December 31, 2012
and 2011, respectively 61,417 27,801
Inventories, net 9,909 5,226
Prepaid income taxes - 6,940
Prepaid expenses and other
current assets 4,900 3,391
Deferred tax assets 5,737 12,093
----- ------
Total current assets 237,276 265,600
Property and equipment, net 2,073 1,970
Purchased technology, net 1,493 2,778
Goodwill - -
Deposits and other assets 70 56
Deferred tax assets 11,519 5,404
------ -----
Total assets $252,431 $275,808
======== ========
LIABILITIES AND SHAREHOLDERS'
EQUITY
Current liabilities:
Accounts payable $13,069 $5,503
Accrued compensation 21,300 11,590
Sales-related reserves 37,376 34,119
Income taxes payable 7,360 -
Other accrued liabilities 11,294 4,509
------ -----
Total current liabilities 90,399 55,721
Lease termination, deferred rent
and other non-current
liabilities 203 261
--- ---
Total liabilities 90,602 55,982
------ ------
Shareholders' equity:
Preferred stock, no par value,
5,334,285 shares authorized;
none outstanding - -
Common stock, no par value,
105,000,000 shares authorized;
58,544,206 and 63,645,781
shares issued and outstanding
at December 31, 2012 and 2011,
respectively 15,938 94,976
Retained earnings 145,851 124,886
Accumulated other comprehensive
income (loss) 40 (36)
--- ---
Total shareholders' equity 161,829 219,826
------- -------
Total liabilities and
shareholders' equity $252,431 $275,808
======== ========
Questcor Pharmaceuticals, Inc.
Consolidated Statements of Cash Flows
(In thousands)
Years Ended December 31,
------------------------
2012 2011 2010
---- ---- ----
(In thousands)
Cash
Flows
From
Operating
Activities
Net
income $197,675 $79,591 $35,071
Adjustments
to
reconcile
net
income
to net
cash
provided
by
operating
activities:
Share-
based
compensation
expense 15,792 7,326 3,739
Deferred
income
taxes 241 (4,896) (1,029)
Amortization
of
investments 1,330 1,250 678
Depreciation
and
amortization 1,219 1,044 546
Impairment
of
goodwill
and
intangibles 987 299 -
Loss on
disposal
of
property
and
equipment 72 11 -
Changes
in
operating
assets
and
liabilities:
Accounts
receivable (33,616) (16,673) 3,705
Inventories (4,683) (1,500) (348)
Prepaid
income
taxes 6,940 (3,408) (3,532)
Income
taxes
payable 7,360 - -
Prepaid
expenses
and
other
current
assets (1,509) (1,527) (702)
Accounts
payable 7,566 1,634 (9,052)
Accrued
compensation 9,710 7,432 2,018
Sales-
related
reserves 3,257 12,608 6,589
Other
accrued
liabilities 6,780 2,526 (255)
Other
non-
current
liabilities (84) (118) (871)
--- ---- ----
Net cash
provided
by
operating
activities 219,037 85,599 36,557
------- ------ ------
Cash
Flows
From
Investing
Activities
Purchase
of
short-
term
investments (145,384) (162,301) (106,647)
Proceeds
from the
sale and
maturities
of
short-
term
investments 191,105 112,636 62,560
Purchase
of
property,
equipment
and
leasehold
improvements (1,065) (1,823) (713)
Changes
in
deposits
and
other
assets (14) 9 645
--- --- ---
Net cash
provided
by
/(used
in)
investing
activities 44,642 (51,479) (44,155)
------ ------- -------
Cash
Flows
From
Financing
Activities
Income
tax
benefit
realized
from
share-
based
compensation
plans 7,488 17,712 1,335
Issuance
of
common
stock,
net 6,335 6,582 1,942
Dividends
paid (23,533) - -
Repurchase
of
common
stock (261,830) (11,453) -
-------- ------- ---
Net cash
(used
in) /
provided
by
financing
activities (271,540) 12,841 3,277
-------- ------ -----
(Decrease)
/
increase
in cash
and
cash
equivalents (7,861) 46,961 (4,321)
Cash and
cash
equivalents
at
beginning
of year 88,469 41,508 45,829
------ ------ ------
Cash and
cash
equivalents
at end
of year $80,608 $88,469 $41,508
======= ======= =======
Supplemental
Disclosures
of Cash
Flow
Information:
Cash
paid
for
interest $23 $16 $7
=== === ===
Cash
paid
for
income
taxes $77,556 $25,278 $23,185
======= ======= =======
Supplemental
disclosure
of non-
cash
investing
and
financing
activities:
Capital
lease
obligation $31 $34 $ -
=== === ==========
SOURCE Questcor Pharmaceuticals, Inc.